A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference18 articles.
1. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA;Kawai;J Am Coll Cardiol,1997
2. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction;Kabenoto;Jpn Circ J,1990
3. Population genetics of the angiotensin-converting enzyme in Chinese;Lee;Br J Clin Pharmacol,1994
4. Outcome of hypertension management in Asian Americans;Hui;Arch Intern Med,1997
5. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study;Gore;Circulation,1991
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Platelet Membrane-Coated r-SAK Improves Thrombolytic Efficacy by Targeting Thrombus;ACS Applied Materials & Interfaces;2024-04-16
2. Long-Term Prognosis of Different Reperfusion Strategies for ST-Segment Elevation Myocardial Infarction in Chinese County-Level Hospitals: Insight from China Acute Myocardial Infarction Registry;BIOMED ENVIRON SCI;2023
3. Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: a randomized non-inferiority trial;Chinese Medical Journal;2023-06-02
4. Systemic reduced‐dose alteplase for diffuse pulmonary thrombi in a COVID‐19 patient;Clinical Case Reports;2023-03
5. Fibrinolytic therapy use for ST-segment elevation myocardial infarction and long-term outcomes in China: 2-year results from the China Acute Myocardial Infarction Registry;BMC Cardiovascular Disorders;2023-02-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3